Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 60

Sort by

Sort Order Select

Journal Articles

Targeting the compass complex to overcome resistance in KMT2A-rearranged Acute Myeloid Leukemia

Sandhya Dhiman, Vikramjit Dhillon, Jeff Justin Aguilar, Julie Boerner, Yang Shi, Jay Yang, Suresh Kumar Balasubramanian

Blood (2025) 146 (Supplement 1): 1517.

https://doi.org/10.1182/blood-2025-1517

Published: 2025

Journal Articles

Multiomics-guided ex vivo drug sensitivity testing in Relapsed/Refractory Acute Myeloid Leukemia

Jeff Justin Aguilar, Vikramjit Dhillon, Sikander Chohan, Dakshin Padmanabhan, Sushmitha Nanja Reddy, Asmita Shukla, Nagasai Yalavarthi, Anisha Rajavel, Sonubar Virk, Breanna Williams, Julie Boerner, Yang Shi, Jay Yang, Suresh Kumar Balasubramanian

Blood (2025) 146 (Supplement 1): 3496.

https://doi.org/10.1182/blood-2025-3496

Published: 2025

Journal Articles

Asciminib as initial therapy with addition of lower dose tyrosine kinase inhibitors (TKIs) for patients with chronic myeloid leukemia who do not achieve optimal response or a deep molecular remission

James Thompson, Lisa Rein, Michael Mauro, Srinivas Tantravahi, Jay Yang, Arielle Baim, Sonia Maldonado-Schmidt, Claire Olig, Kathryn Flynn, Yan Gao, Jerald Radich, Ehab Atallah, Jorge Cortes

Blood (2025) 146 (Supplement 1): 7311.

https://doi.org/10.1182/blood-2025-7311

Published: 2025

Journal Articles

Prognostic impact of pre-transplant IPSS-m risk downstaging in Myelodysplastic Syndromes

Asmita Shukla, Jeff Justin Aguilar, Vikramjit Dhillon, Sikander Chohan, Nagasai Yalavarthi, Dakshin Padmanabhan, Sushmitha Nanja Reddy, Anisha Rajavel, Jay Yang, Jaroslaw Maciejewski, Suresh Kumar Balasubramanian

Blood (2025) 146 (Supplement 1): 3872.

https://doi.org/10.1182/blood-2025-3872

Published: 2025

Journal Articles

Treatment free remission after asciminib (ABL001) based therapy in chronic Phase chronic myeloid leukemia (CP-CML) patients who relapsed after a prior attempt at TKI discontinuation-h jean khoury cure CML consortium study HJKC3-0003

Michael Mauro, Lisa Rein, Jay Yang, Srinivas Tantravahi, Sonia Maldonado-Schmidt, Claire Olig, Alexander Hinman, Arielle Baim, Jerald Radich, Kathryn Flynn, Ehab Atallah

Blood (2025) 146 (Supplement 1): 7293.

https://doi.org/10.1182/blood-2025-7293

Published: 2025

Journal Articles

Management and outcomes of patients diagnosed with chronic myeloid leukemia in blast Phase: A multicenter analysis by the h jean khoury cure CML consortium

Blood (2025) 146 (Supplement 1): 904.

https://doi.org/10.1182/blood-2025-904

Published: 2025

Journal Articles

Olutasidenib monotherapy in patients with mIDH1 Acute Myeloid Leukemia who received prior intensive chemotherapy

Jay Yang, Joseph Jurcic, Christian Recher, Pierre Fenaux, Andrew Wei, Antonio Curti, Justin Watts, Eunice Wang, Brian Jonas, Jorge Cortes, Aaron Sheppard, Sophia Wang, Stephane De Botton

Blood (2025) 146 (Supplement 1): 5213.

https://doi.org/10.1182/blood-2025-5213

Published: 2025

Journal Articles

A phase I dose escalation and expansion trial of lyt-200 (a First-In-Class Anti-Galectin-9 Antibody) alone and in combination with venetoclax/HMA in Relapsed/Refractory AML/MDS

Aleksandra Filipovic, Amir Fathi, Noah Merin, Keri Maher, Rabin Niroula, Dale Schaar, Guenther Koehne, Joseph Maly, Jay Yang, Deepa Jeyakumar

Blood (2025) 146 (Supplement 1): 1648.

https://doi.org/10.1182/blood-2025-1648

Published: 2025

Journal Articles

Clinical characteristics and response in olutasidenib-treated Relapsed/Refractory mIDH1 Acute Myeloid Leukemia (AML) patients with stable disease following two treatment cycles

Justin Watts, Eunice Wang, Brian Jonas, William Donnellan, Jay Yang, Karen Seiter, Andrew Wei, Stephane De Botton, Amber Thomassen, Hua Tian, Jorge Cortes

Blood (2025) 146 (Supplement 1): 1659.

https://doi.org/10.1182/blood-2025-1659

Published: 2025

Journal Articles

Clonal Evolution of TP53 Configurations with Treatment Predict Prognosis in Myeloid Neoplasms

Dakshin Padmanabhan, Jeff Aguilar, Paul Kim, Sandhya Dhiman, Asmita Shukla, Vikram Dhillon, Sushmitha Nanja Reddy, David Carr, Jay Yang, Julie Boerner, Jaroslaw Maciejewski, Suresh Kumar Balasubramanian

Blood (2024) 144 (Supplement 1): 1540.

https://doi.org/10.1182/blood-2024-210037

Published: 2024

Journal Articles

Time to Response and Overall Survival in Patients with m IDH1 Relapsed/Refractory Acute Myeloid Leukemia Treated with Olutasidenib

Eunice S. Wang, Jorge E. Cortes, Justin M. Watts, Brian A. Jonas, Andrew H Wei, Jay Yang, Joseph G Jurcic, Gail J. Roboz, Karen Seiter, Alice Mims, Karen Yee, Brent Ferrell, Shira N. Dinner, William B. Donnellan, William Blum, Francois Di Trapani, Hua Tian, Stephane De Botton

Blood (2024) 144 (Supplement 1): 1514.

https://doi.org/10.1182/blood-2024-198504

Published: 2024

Journal Articles

U.S. Expert Consensus on Defining Intolerance to Tyrosine Kinase Inhibitor Treatment in Chronic Phase Chronic Myeloid Leukemia (CML)

Ehab L. Atallah, Michael S. Broder, Onyee Chan, Hannah Dalglish, Kathryn E. Flynn, Jeffrey Gilreath, Marisa Hine, Anthony M. Hunter, Michael J. Mauro, Javier Pinilla-Ibarz, Lindsay A.M. Rein, Neil P. Shah, Evan Stemper, Srinivas K Tantravahi, Jay Yang

Blood (2024) 144 (Supplement 1): 5052.

https://doi.org/10.1182/blood-2024-194617

Published: 2024

Journal Articles

Longitudinal Sequencing to Investigate Clonal Evolution in Myeloid Neoplasms

Asmita Shukla, Dakshin Padmanabhan, Paul Kim, Jeff Aguilar, Sushmitha Nanja Reddy, Vikram Dhillon, David Carr, Jay Yang, Julie Boerner, Suresh Kumar Balasubramanian

Blood (2024) 144 (Supplement 1): 4254.

https://doi.org/10.1182/blood-2024-212206

Published: 2024

Journal Articles

PF-08046040 (SEA-CD70), a Nonfucosylated CD70-Directed Antibody, in Combination with Azacitidine for Patients with Myelodysplastic Syndromes (MDS): A Phase 1 Dose-Finding and Dose Expansion Study

Nicole R. Grieselhuber, Praneeth Baratam, Anjali S. Advani, Abdulraheem Yacoub, Don A. Stevens, Ahmed Aribi, Ben K. Tomlinson, Jay Yang, Pankit Vachhani, Joseph G Jurcic, Caspian H. Oliai, Jessica Liegel, Edward Pearson, Anna Van Rhenen, Marcello Rotta, Kapil Rathi, Juan Pinelli, Tara Chen, Amir T. Fathi

Blood (2024) 144 (Supplement 1): 1840.

https://doi.org/10.1182/blood-2024-199634

Published: 2024

Journal Articles

Olutasidenib Alone or in Combination with Azacitidine in Patients with m IDH1 Myelodysplastic Syndromes/Neoplasms: Final 5-Year Data

Jorge E. Cortes, Justin M. Watts, Eunice S. Wang, Jay Yang, Shira N. Dinner, Maria R. Baer, Gail J. Roboz, William B. Donnellan

Blood (2024) 144 (Supplement 1): 4600.

https://doi.org/10.1182/blood-2024-204039

Published: 2024

Journal Articles

Clinical and Molecular Characteristics of RAS and RAS-like Mutational Signature in Acute Myeloid Leukemia

Vikram Dhillon, Jeff Aguilar, Paul Kim, Dakshin Padmanabhan, Jay Yang, Gregory Dyson, David Carr, Jaroslaw Maciejewski, Suresh Kumar Balasubramanian

Blood (2024) 144 (Supplement 1): 842.

https://doi.org/10.1182/blood-2024-212313

Published: 2024

Journal Articles

Combination of Olutasidenib and Azacitidine Induces Durable Complete Remissions in m IDH1 Acute Myeloid Leukemia: A Multicohort Open-Label Phase 1/2 Trial

Jorge E. Cortes, Gail J. Roboz, Justin M. Watts, Maria R. Baer, Brian A. Jonas, Gary J. Schiller, Karen Yee, Brent Ferrell, Jay Yang, Eunice S. Wang, William Blum, Alice Mims

Blood (2024) 144 (Supplement 1): 2886.

https://doi.org/10.1182/blood-2024-201710

Published: 2024

Journal Articles

First Results of Asciminib As Initial Therapy with Addition of Lower Dose Tyrosine Kinase Inhibitors for Patients with Chronic Myeloid Leukemia Who Do Not Achieve a Deep Molecular Remission (ALERT CML) from the H Jean Khoury Cure CML Consortium (HJKC3)

Jorge E. Cortes, Michael J. Mauro, Alexis Visotcky, Srinivas K Tantravahi, James E Thompson, Jay Yang, Arielle Baim, Yan Gao, Sonia Maldonado-Schmidt, Claire Olig, Kathryn E. Flynn, Jerald P. Radich, Ehab L. Atallah

Blood (2024) 144 (Supplement 1): 6601.

https://doi.org/10.1182/blood-2024-207884

Published: 2024

Journal Articles

An Investigator Initiated Study of RCHOP in Combination with Selinexor (KPT-330) in Diffuse Large B Cell Lymphoma and Richter Transformation

Dipenkumar Modi, Jay Yang, Seongho Kim, Asfar Azmi, Emily Tolksdorf, Christiane A. Houde, Jeffrey A. Zonder

Blood (2024) 144 (Supplement 1): 3123.4.

https://doi.org/10.1182/blood-2024-209059

Published: 2024

Journal Articles

Management and Outcomes of Patients Diagnosed with Chronic Myeloid Leukemia in Blast Phase: A Multicenter Analysis By the H Jean Khoury Cure CML Consortium

Blood (2024) 144 (Supplement 1): 2426.

https://doi.org/10.1182/blood-2024-207278

Published: 2024

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Targeting the compass complex to overcome resistance in KMT2A-rearranged Acute Myeloid Leukemia

Multiomics-guided ex vivo drug sensitivity testing in Relapsed/Refractory Acute Myeloid Leukemia

Asciminib as initial therapy with addition of lower dose tyrosine kinase inhibitors (TKIs) for patients with chronic myeloid leukemia who do not achieve optimal response or a deep molecular remission

Prognostic impact of pre-transplant IPSS-m risk downstaging in Myelodysplastic Syndromes

Treatment free remission after asciminib (ABL001) based therapy in chronic Phase chronic myeloid leukemia (CP-CML) patients who relapsed after a prior attempt at TKI discontinuation-h jean khoury cure CML consortium study HJKC3-0003

Management and outcomes of patients diagnosed with chronic myeloid leukemia in blast Phase: A multicenter analysis by the h jean khoury cure CML consortium

Olutasidenib monotherapy in patients with mIDH1 Acute Myeloid Leukemia who received prior intensive chemotherapy

A phase I dose escalation and expansion trial of lyt-200 (a First-In-Class Anti-Galectin-9 Antibody) alone and in combination with venetoclax/HMA in Relapsed/Refractory AML/MDS

Clinical characteristics and response in olutasidenib-treated Relapsed/Refractory mIDH1 Acute Myeloid Leukemia (AML) patients with stable disease following two treatment cycles

Clonal Evolution of TP53 Configurations with Treatment Predict Prognosis in Myeloid Neoplasms

Time to Response and Overall Survival in Patients with m IDH1 Relapsed/Refractory Acute Myeloid Leukemia Treated with Olutasidenib

U.S. Expert Consensus on Defining Intolerance to Tyrosine Kinase Inhibitor Treatment in Chronic Phase Chronic Myeloid Leukemia (CML)

Longitudinal Sequencing to Investigate Clonal Evolution in Myeloid Neoplasms

PF-08046040 (SEA-CD70), a Nonfucosylated CD70-Directed Antibody, in Combination with Azacitidine for Patients with Myelodysplastic Syndromes (MDS): A Phase 1 Dose-Finding and Dose Expansion Study

Olutasidenib Alone or in Combination with Azacitidine in Patients with m IDH1 Myelodysplastic Syndromes/Neoplasms: Final 5-Year Data

Clinical and Molecular Characteristics of RAS and RAS-like Mutational Signature in Acute Myeloid Leukemia

Combination of Olutasidenib and Azacitidine Induces Durable Complete Remissions in m IDH1 Acute Myeloid Leukemia: A Multicohort Open-Label Phase 1/2 Trial

First Results of Asciminib As Initial Therapy with Addition of Lower Dose Tyrosine Kinase Inhibitors for Patients with Chronic Myeloid Leukemia Who Do Not Achieve a Deep Molecular Remission (ALERT CML) from the H Jean Khoury Cure CML Consortium (HJKC3)

An Investigator Initiated Study of RCHOP in Combination with Selinexor (KPT-330) in Diffuse Large B Cell Lymphoma and Richter Transformation

Management and Outcomes of Patients Diagnosed with Chronic Myeloid Leukemia in Blast Phase: A Multicenter Analysis By the H Jean Khoury Cure CML Consortium

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only